

26 NOVEMBER 2020

AGM COMPANY UPDATE

ASX ANNOUNCEMENT

Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) is pleased to provide a copy of its Managing Director’s Company Update presentation in advance of the Company’s Annual General Meeting today at 2pm (AWST).

ENDS

BY ORDER OF THE BOARD

A handwritten signature in dark ink, appearing to be "Alistair Warren", written over a horizontal line.

Alistair Warren
Company Secretary

For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: alistair@lgpharma.com.au
M: +61 8 6280 0050

Fleta Solomon
Managing Director
Little Green Pharma
E: fleta@lgpharma.com.au
M: +41 782 260 200





ANNUAL GENERAL MEETING

COMPANY UPDATE

26 NOVEMBER 2020



Disclaimer



Disclaimer

This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 215) ("LGP") and its activities current as at the date of this presentation. The information in this presentation is of general background and does not purport to be complete or to contain all the information which a prospective investor may require in evaluating a possible investment in LGP or that would be required in a prospectus or a product disclosure statement prepared in accordance with the Corporations Act 2001 (Cth) (Corporations Act).

It should be read in conjunction with LGP's other periodic and continuous disclosure announcements filed with the Australian Securities Exchange, which are available at www.asx.com.au.

This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire LGP's shares or other securities. This document does not constitute or contain an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in LGP.

No liability

The information contained in this document has been prepared in good faith by LGP, however no guarantee representation or warranty expressed or implied is or will be made by any person (including LGP and its affiliates and their directors, officers, employees, associates, advisers and agents) as to the accuracy, reliability, correctness, completeness or adequacy of any statements, estimates, options, conclusions or other information contained in this document.

To the maximum extent permitted by law, LGP and its affiliates and their directors, officers, employees, associates, advisers and agents each expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom.

Statements in this document are made only as of the date of this document unless otherwise stated and the information in this document remains subject to change without notice.

Not financial product advice

This document does not constitute financial product advice or take into account your investment objectives, taxation situation, financial situation or needs. This document consists purely of factual information and does not involve or imply a recommendation of a statement of opinion in respect of whether to buy, sell or hold a financial product.

An investment in LGP is considered to be speculative in nature. Before making any investment decision in connection with any acquisition of securities, investors should consult their own legal, tax and/or financial advisers in relation to the information in, and action taken on the basis of, this document.

Forward looking statements

Certain information in this document refers to the intentions of LGP, but these are not intended to be forecasts, forward looking statements or statements about the future matters for the purposes of the Corporations Act or any other applicable law. The occurrence of the events in the future are subject to risk, uncertainties and other actions that may cause LGP's actual results, performance or achievements to differ from those referred to in this document. Accordingly LGP and its affiliates and their directors, officers, employees and agents do not give any assurance or guarantee that the occurrence of these events referred to in the document will actually occur as contemplated. Past performance is no guarantee of future performance.

This presentation may contain forward-looking statements including statements regarding our intent, belief or current expectations with respect to LGP's business and operations, market conditions, results of operations and financial condition, specific provisions and risk management practices. When used in this presentation, the words 'likely', 'estimate', 'project', 'intend', 'forecast', 'anticipate', 'believe', 'expect', 'may', 'aim', 'should', 'potential' and similar expressions, as they relate to LGP and its management, are intended to identify forward-looking statements. Forward looking statements involve known and unknown risks, uncertainties and assumptions and other important factors that could cause the actual results, performances or achievements of LGP to be materially different from future results, performances or achievements expressed or implied by such statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date thereof.

Acceptance

By attending LGP's Annual General Meeting, or accepting, accessing or reviewing this document you acknowledge and agree to the "Disclaimer" as detailed above.

Corporate Overview

Little Green Pharma Overview

- Vertically integrated medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution
- Indoor ~3 tonne flower / ~300,000 bottles p.a. cultivation facility and GMP-licensed manufacturing facility in Western Australia
- Supplies medical-grade cannabis products to Australian and overseas markets

Capital structure


Current Share Price ¹	\$0.45
Shares Outstanding ^{2,3}	134,467,663
Options and Performance Rights on Issue	21,051,536
Market Capitalisation (undiluted)	~\$60.5 million
Cash Reserves (30 September 2020)	~\$4.2 million
Enterprise Value	~\$56.3 million

1. Source: IRESS - As at 25 November 2020
2. 1,561,636 shares are escrowed until 5 February 2021
3. 54,034,703 shares are escrowed 24 months from date of listing (20 Feb 2020)
4. As at 31 October 2020

Shareholders⁴

Shareholder	Shareholding	Ownership
Elixer Ltd	29.5m	21.9%
Fleta Solomon	19.6m	14.6%
TIGA Trading Pty Ltd	7.7m	5.7%
Angus Caithness	5.7m	4.2%
Top 20 shareholders	91.0m	67.6%
Board ownership	29.4m	21.9%


Register Breakdown⁴



We are passionate about transforming lives. This drives our desire to grow and produce quality cannabis medicines that are safe, effective and affordable. It's the heart of everything we do and defines our culture. This is our purpose – to reimagine cannabis medicine and do extraordinary things for our patients.


We are proud of what we've done and where we're going.

We are Little Green Pharma.



Our Business Model Captures Value

LGP operates across the medicinal cannabis supply chain



1. GMP is Good Manufacturing Practice (GMP) licensed by Australia's Therapeutic Goods Administration (TGA). Australia has a Mutual Recognition Agreement (MRA) with the EU
2. LGP has an exclusive agreement with a GMP licensed medicinal cannabis manufacturer who may only terminate the agreement after 22 November 2023 on 12 months' notice.

Growth Strategy

Little Green Pharma has a track record of sales growth with a clear pathway to increasing margins and driving significant revenue growth in Australia and offshore markets



1

Established sales platform in Australia

Currently selling four LGP-branded THC and CBD cannabis medicines in Australia with imminent release of medicinal cannabis flower products



2

Clear pathway to international sales

Sales agreements with distributors in the UK and Germany for the sale, export and distribution of LGP's cannabis medicines



3

Patient access and product innovation

Driving patient access through education platforms. Clinical investigations and research projects underway to develop innovative new delivery systems



Why these are strategically important:

Sales in Australia demonstrate market validity and generate immediate cash flow to support development of international pathways




Early-mover commercial volumes in international markets the primary mechanism to secure and grow offshore market share



Focus on high-quality cannabis medicines now and developing unique delivery systems for patients in the future to further grow and maintain market share

Track Record of Growing Patient Access

Strong growth in sales and patients using LGP products in Australia



Capability - Access to Raw Biomass



Internal Cultivation and External Raw Biomass

- ✓ Cultivation experience suggests indoor GACP cultivation facility capacity re-rating of 300,000 (50ml) bottles equivalent of cannabis oils (~3,000 kg flower p.a.)
- ✓ First crop harvested from expanded facility
- ✓ Expanded facility improves supply reliability and capacity
- ✓ Option to double current cultivation capacity with further expansion if necessary
- ✓ Existing supply lines with multiple suppliers of high-quality third-party raw material to supplement production capacity



Capability - Manufacturing



Fully Licensed and Diversified Manufacturing Capability

- ✓ ODC and TGA-GMP licensed in-house manufacturing facility capable of producing:
 - flower;
 - extracts (oils);
 - tinctures; and
 - active pharmaceutical ingredients (APIs)
- ✓ EU-GMP compliance allows LGP to deliver products to countries in Europe and the Americas
- ✓ Additional high-volume manufacturing and R&D capability with exclusive third party GMP licensed partner¹
- ✓ Ready for production at scale to support offshore sales
- ✓ Diversified manufacturing enables de-bottlenecking and cost efficiencies with a focus on driving margin improvement



1. LGP has an exclusive agreement with a TGA-GMP certified medicinal cannabis manufacturer who may only terminate the agreement after 22 November 2023 on 12 months' notice.

Facility Tour



Patient Access and Education




Partnership with HIF Australia

- ✓ Entered into strategic partnership with Health Insurance Fund of Australia (HIF)
- ✓ HIF the first private health insurance fund to publicly support and rebate cannabis medicines, with eligible members to receive a rebate of up to \$105¹
- ✓ HIF to support large scale study and further research



Proprietary Medical Portal

- ✓ LGP has launched a proprietary Medical Portal to drive patient access and education for medical professionals
- ✓ The Medical Portal is focussed on:
 - the latest regulatory framework;
 - prescriber support on access pathways, clinical evidence, and research
 - access to LGP product catalogue; and
 - exclusive educational resources and insights on medicinal cannabis



1. Subject to individual policy caps

Sales and Distribution



Commercial Sales Volumes into International Markets

- ✓ Strong domestic growth in sales, prescribers and patients
- ✓ LGP inhouse GMP licence recognized in EU
- ✓ Australian-first export of commercial shipment to Germany
- ✓ Third global medicinal cannabis producer to deliver full plant cannabis extract medicines into Germany after Tilray and Aurora
- ✓ First cannabis flower shipment to Germany anticipated in Q1 CY 2021
- ✓ Building German business development and operational team
- ✓ Ongoing exports of cannabis medicines into UK
- ✓ Ongoing distribution network growth in EU and South America



News Flow – making solid progress

Significant commercial progress as LGP executes growth strategy



- ✓ First commercial quantity delivered into the UK
- ✓ Grant of TGA GMP manufacturing licence and commissioning of facility
- ✓ Successful first harvest and capacity increase in expanded facility
- ✓ Partnership with national health insurer
- ✓ Fulfilment of CC Pharma order into Germany (2,400 bottles)
- 🏥 Commencement of first ethics approved large scale study
- 🚚 Delivery of first products to South America and New Zealand
- 🚚 Delivery of first flower products into Germany
- 🏭 Expansion of product line with new *LGP Classic 1:100 CBD* medicine
- 🏭 Successful application of cannabis API to ARISE technology

Australian medicinal cannabis oils

2018
First
Australian
products





QUESTIONS & ANSWERS